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 Although an ample characterization of 
the model was performed, vitamin D 
levels were not addressed, which might 
be relevant when a vitamin D analog is 
used as pharmacological treatment. 
Similar confirmation should be per-
formed in KTx patients under CsA-
based immunosuppressive therapy, in 
order to estimate whether vitamin D 
suppression is a key factor for the kidney 
injury and, consequently, a feasible tar-
get for renoprotective pharmacological 
post-transplantation therapy. Further-
more, as a complement to the study by 
Park  et al. , 6 the protective role of pari-
calcitol against other relevant contribu-
tors to CIN might also be estimated, 
including: the well-accepted renal vas-
cular impairment due to increased vaso-
constrictors, such as thromboxane A 2 
and endothelin 1, and / or decreased 
vasodilators, such as prostacyclin and 
NO; oxidative stress, namely through 
inducible NO synthase production of 
NO that will react with superoxide 
(O 2  ·  −   ), thus generating peroxynitrite 
(ONOO   −   ), a deleterious reactive spe-
cies; the activity of the RAAS, particu-
larly due to angiotensin II overproduction 
and / or overactivity; and the activity of 
the sympathetic nervous system, via 
noradrenaline and adrenaline produc-
tion and reactivity ( Figure 1b ). Accord-
ing to several previous reports in 
experimental models and in humans, 
these are pivotal factors for CsA-induced 
nephrotoxicity and, thus, deserve better 
clarifi cation. 10 
 In conclusion, the effi  cacy of paricalci-
tol in the prevention and attenuation of 
CsA-induced nephrotoxicity needs to be 
confi rmed by more ample research in ani-
mal models in order for it to be further 
considered as suitable for study in pro-
spective randomized trials. At the very 
least, urologists and nephrologists need 
to be aware of the potential renoprotec-
tive eff ects of paricalcitol against CIN, 
and preclinical data, such as those 
reported by Park  et al. , 6 must be consid-
ered in the design of clinical trials in post-
transplantation CsA-induced kidney 
injury. 
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 Coronary artery calcification scoring 
(CACS) by computed tomography is a 
useful method to estimate the likelihood 
of coronary heart disease and all-cause 
mortality in the general population. In 
fact, the predictive value of CACS is sever-
alfold higher than that of the Framingham 
Risk Score 1 in patients without chronic 
kidney disease. Currently, the main value 
of CACS lies in the estimation of 
 cardiovascular events, as CACS increases 
the discriminatory capacity of models that 
use conventional risk factors. 
 In patients with chronic kidney dis-
ease (CKD), however, CACS was initially 
used to identify pathophysiologic mech-
anisms of vascular calcifi cation. Braun 
 et al. , 2 who were the first to measure 
CACS by electron beam computed tom-
ography in dialysis patients, found no 
association between calcium, phosphate, 
the calcium  × phosphate product, and 
the extent of CACS. Interestingly, they 
also registered no correlation between 
CACS and coronary angiograms. Several 
subsequent studies focused on the exces-
sive calcifi cation seen in dialysis patients, 
and the persistent conviction that 
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 High coronary artery calcification score (CACS) assessed by computed 
tomography is related to mortality in asymptomatic patients with 
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patients with end-stage renal disease and is unknown in patients with 
pre-terminal renal failure. Chiu and co-workers provide evidence that 
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 coronary calcification reduces life 
expectancy. To date, more than 30 stud-
ies have been performed in dialysis 
patients. Th e extent of coronary calcifi -
cation has been shown to correlate with 
several factors infl uencing, or associated 
with, calcifi cation or phosphate metabo-
lism, such as osteoprotegerin, fetuin, 
pulse wave velocity, troponin T, matrix 
Gla protein, or ENPP1. However, despite 
an extensive search, evidence for the the-
sis that coronary calcifi cation infl uences 
mortality is still scarce and contradic-
tory. Th ere is also no conclusive evidence 
of the association between coronary 
angiograms and the extent of calcifi ca-
tion. Th e same uncertainty is true for the 
reduction or prevention of vascular cal-
cifi cation by therapeutic means. 
 As vascular calcification may occur 
early in patients with chronic renal fail-
ure, an increasing number of investigators 
have focused on CACS in CKD patients 
not yet on dialysis. Chiu  et al. 3 (this issue) 
now describe the correlation between 
coronary artery calcifi cation and all-cause 
mortality in patients with stage 1 – 5 CKD 
(without dialysis). All patients had a 
history of diabetes for at least 10 years and 
high levels of protein excretion. Kidney 
biopsies had been performed in a small 
minority of patients. However, their 
medical history revealed that the large 
majority had diabetic nephropathy. Th is 
subgroup of patients with chronic kidney 
failure is subject to a high risk of mortality 
and cardiovascular complications. Com-
pared with the general population, in 
2007 the relative risk of all-cause mortal-
ity in patients with stage 1 – 5 CKD and 
diabetes was 1.8. Th e risk increased to 
3.35 when the patients also had cardio-
vascular disease. 4 In the study by Chiu 
 et al. , 3 patients with the highest coronary 
calcifi cation score (Agatston score   400) 
also had the highest all-cause mortality. 
Other factors, such as serum albumin, 
kidney function, and ethnicity, were pre-
dictive of mortality as well, but the mul-
tivariate analysis confi rmed a high risk of 
mortality in patients with coronary calci-
fi cation. Th e study is remarkable insofar 
as it shows, for the fi rst time, a higher rate 
of mortality in predialysis patients with 
high coronary calcifi cation scores. How-
ever, the authors used all-cause mortality 
as an end point. In smaller studies, it is 
frequently used as surrogate parameter 
instead of cardiovascular calcifi cation. 
Therefore, it remains unclear whether 
cardiovascular disease was indeed the 
cause of death. Although survival was 
correlated to baseline values and no 
follow-up measurements were per-
formed, it may be assumed that patients 
with high baseline values also had the 
strongest progression of calcification. 
Age and baseline CACS have been 
proven to be the strongest predictors of 
progressive coronary calcification. 5 
 Th is leads to the main issue of this study: 
If CACS predicts mortality already in this 
early stage of CKD, is there any way of 
infl uencing the progression of calcifi cation 
or even reversing it? And if progression of 
coronary calcifi cation can be infl uenced, 
does this also improve survival? 
 The absence of studies on this issue 
makes both questions diffi  cult to answer. 
Coronary calcifi cation in patients with 
CKD has been traditionally distinguished 
from calcifi cation in patients with normal 
kidney function. It is generally assumed 
that calcium deposits occur predomi-
nantly in the medial wall of the artery in 
CKD, but in the intima of patients without 
CKD. Medial sclerosis is also known as 
M ö nckeberg ’ s sclerosis, named after 
Johann Georg M ö nckeberg, a German 
pathologist, who fi rst described this entity 
at the beginning of the last century. To 
further diff erentiate between medial and 
intimal sclerosis, the former is also known 
as arteriosclerosis and the latter athero-
sclerosis, that is, sclerosis of an intimal 
atheroma or plaque. Th e unequal distribu-
tion of vascular calcifi cation in the normal 
population and in patients with chronic 
renal failure is believed to have clinical 
 Figure 1  |  Coronary artery pathologies in patients with and without chronic kidney disease. Top row: Proximal segment of the left anterior 
descending coronary artery in a patient with CKD 5D. ( a ) Calcification of intimal atheromatous plaque (surrounded by arrowheads). ( b ) Severe stenosis in 
the distal segment of the same artery. ( c ) Osteopontin positive in immunohistochemistry. Bottom row: ( d ) Large necrotic core with little calcification. 
( e ) Distal segment of the same artery without stenosis. ( f ) CD68-positive macrophage accumulation in the plaque. (Reprinted from ref. 6.) 
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consequences. Unstable and yet non-calci-
fied intimal atheromatous plaques in 
atherosclerosis are prone to rupture and 
may occlude the vessel. Medial arterio-
sclerosis, on the other hand, causes stiff -
ening of the arteries and, only in rare 
cases, narrowing of the arterial lumen. 
 But are these truly diff erent diseases? 
In a recent autopsy study of patients with 
diff erent stages of chronic renal failure, 
Nakamura  et al. reported the occurrence 
of intimal sclerosis in all CKD stages, but 
M ö nckeberg ’ s sclerosis in only 7 of 39 
patients with CKD 4 – 5D. 6 Notably, 
medial calcifi cation was generally associ-
ated with intimal sclerosis ( Figure 1 ). 
Th is supports the hypothesis of McCul-
lough  et al. , 7 according to which medial 
calcification is not a distinct disease 
entity, but an amplifi cation of preexisting 
atherosclerosis. 
 In the study by Chiu  et al. , 3 the mean 
estimated glomerular fi ltration rate was 
52 ± 26  ml / min. Therefore, it may be 
assumed that the majority of patients had 
intimal calcifi cation. However, coronary 
calcification was more pronounced 
because of the additional presence of dia-
betes, and the medial wall was probably 
more aff ected than it was in CKD patients 
without diabetes. Th us, with reference to 
the association between intimal and medial 
calcifi cation, the best way to delay dialysis-
associated vascular calcifi cation would be 
to prevent atherosclerosis by avoiding or 
treating traditional risk factors. 
 Once it is present, reversal of coronary 
calcifi cation appears to be impossible. 
Only one study reported improvement of 
CACS by treatment with the calcium-free 
phosphate binder sevelamer. 8 Not sur-
prisingly, the study was sponsored by the 
manufacturer, which might have biased 
the results. However, two subsequent 
publications reported excessive progres-
sion of coronary artery calcifi cation dur-
ing the use of sevelamer, and no diff erence 
in the intake of calcium carbonate. 9 At 
least one of these studies was sponsored 
by the manufacturer of calcium carbon-
ate (PhosLo), which again may have 
infl uenced the results. Th erefore, it is cur-
rently unknown whether the reduction of 
calcium or the use of a specifi c phosphate 
binder actually influences calcium 
deposits in soft tissue. As long as the 
pharmaceutical industry uses medical 
journals for its advertising campaigns, 
this problem will probably remain unre-
solved. A diff erent approach to counter-
act calcification could be to reduce 
phosphate, which is the main triggering 
agent for intracellular calcium deposits. 10 
Interestingly, higher phosphate levels 
were associated with CACS in a commu-
nity-based cohort investigated for the risk 
of coronary artery disease in young adults 
(CARDIA Study). 11 Th e associations were 
present only in the multivariate analysis, 
and the eff ect was not particularly strong. 
However, from a pathophysiologic point 
of view, reducing phosphate levels might 
be benefi cial, especially in patients with 
CKD. Preliminary fi ndings concerning 
pre-terminal renal failure appear to sup-
port this hypothesis, 9 but we still have a 
long way to go. 
 Th e use of sodium thiosulfate, which 
binds to precipitated calcium, is an entirely 
diff erent approach. In patients with cal-
ciphylaxis, sodium thiosulfate was shown 
to reduce the calcium load and improve 
healing of calcemic arteriolopathy. Th e 
fi rst study concerning the eff ect of sodium 
thiosulfate on coronary calcifi cation in 
hemodialysis patients has been published 
ahead of print and demonstrated delayed 
progression of CACS. 12 
 All of these attempts to reduce coronary 
calcifi cation are based on the belief that 
reversal of calcifi cation also reduces mor-
tality. However, evidence of greater vascu-
lar calcifi cation being directly linked with 
mortality is scarce. In fact, except in 
patients with calciphylaxis, there appears 
to be no specifi c reason why progressive 
calcifi cation should lead to death. Calcifi ed 
coronary plaques, for example, are more 
stable than weak plaques and therefore not 
prone to rupture. CACS is unable to pre-
dict the severity of atherosclerosis and is 
not associated with the likelihood of coro-
nary events. Only a minority of patients 
with severe coronary calcifi cation die from 
a cardiovascular event. Importantly, reduc-
tion of lipid levels by the administration of 
a statin was able to reduce mortality 
despite progression of CACS. 9 It is of 
utmost importance to determine whether 
reduction of coronary calcifi cation does 
improve survival. This issue has been 
investigated in a large number of recent 
studies using diverse treatment strategies 
ranging from lifestyle modifications to 
therapeutic interventions. 
 Chiu  et al. 3 provide crucial additional 
data on the usefulness of CACS in predict-
ing the risk of mortality in patients with 
diff erent stages of CKD. It will now be even 
more important to prove that CACS is not 
a proxy for other risk factors. If so, reversal 
of CACS will translate not into improved 
survival but only into the reduced capacity 
of CACS to predict mortality. 
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